Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 3 od 10  
Back povratak na rezultate
2018, vol. 75, br. 11, str. 1070-1075
Pojava steatoze jetre kod bolesnika sa hroničnim hepatitisom C - iskustvo Kliničkog centra Vojvodine
Klinički centar Vojvodine, Klinika za infektivne bolesti, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet

e-adresatomislav.preveden@mf.uns.ac.rs
Sažetak
Uvod/Cilj. Steatoza jetre se javlja kod oko polovine bolesnika sa hroničnim hepatitisom C. Na njenu pojavu utiču faktori domaćina i faktori virusa, a njen značaj je u tome što smanjuje uspeh antivirusne terapije za lečenje hroničnog hepatitisa C zasnovane na interferonu i što, udružena sa drugim faktorima, pogoršava bolest jetre. Cilj ovog rada bio je da se utvrdi prevalenca i težina steatoze kod obolelih od hroničnog hepatitisa C i da se utvrde faktori koji utiču na njenu pojavu. Metode. Istraživanjem su obuhvaćena 123 bolesnika sa hroničnim hepatitisom C, kod kojih je dijagnoza steatoze jetre postavljena biopsijom jetre i patohistološkim (PH) pregledom. Uslov za pozitivnu PH dijagnozu steatoze jetre bio je da ≥ 5% hepatocita bude zahvaćeno masnom promenom. Na osnovu prisustva steatoze bolesnici su bili podeljeni u dve grupe: 43 ispitanika sa steatozom i 80 bez steatoze. Ispitivan je uticaj pojedinih faktora na nastanak steatoze, uz korišćenje standardnih statističkih metoda. Rezultati. Steatoza jetre nađena je kod 34,96% ispitanika sa hroničnim hepatitisom C, a najveći broj ispitanika (76,74%) imao je blagu steatozu. Od ispitivanih prediktivnih faktora za pojavu steatoze, statističku značajnost u njenoj pojavi imali su povišen indeks telesne mase [body mass index (BMI)], genotip 3 hepatitis C virusa (HCV) i HCV viremija. Zaključak. Steatoza jetre se često javlja kod bolesnika sa hroničnim hepatitisom C i najčešće je blaga. Na pojavu steatoze jetre u našem uzorku najviše su uticali genotip 3 HCV i visina HCV viremije. Steatoza jetre može umanjiti uspeh antivirusne terapije zasnovane na interferonu i može pogoršati tok hronične bolesti jetre. Zbog toga je treba prepoznati, lečiti i ukloniti.
Reference
Abenavoli, L. (2014) Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World Journal of Gastroenterology, 20(41): 15233
Adinolfi, L., Rinaldi, L., Guerrera, B., Restivo, L., Marrone, A., Giordano, M., Zampino, R. (2016) NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences, 17(6): 803
Adinolfi, L.E., Restivo, L., Marrone, A. (2013) The predictive value of steatosis in hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology, 7(3): 205-213
Ahmed, M. (2015) Non-alcoholic fatty liver disease in 2015. World Journal of Hepatology, 7(11): 1450
Ben, M.D. (2014) Modern approach to the clinical management of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 20(26): 8341
Calzadilla, B.L., Adams, L. (2016) The Natural Course of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 17(5): 774
Castera, L. (2004) Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut, 53(3): 420-424
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., Sanyal, A.J. (2012) The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55(6): 2005-2023
Chen, S.L., Morgan, T.R. (2006) The Natural History of Hepatitis C Virus (HCV) Infection. International Journal of Medical Sciences, : 47-52
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASLEASD- EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol, 64(6): 1388-402
Flisiak, R., Pogorzelska, J., Flisiak-Jackiewicz, M. (2017) Hepatitis C: efficacy and safety in real life. Liver International, 37: 26-32
Gambarin-Gelwan, M. (2013) Viral hepatitis, non-alcoholic fatty liver disease and alcohol as risk factors for hepatocellular carcinoma. Chin Clin Oncol, 2(4): 32
González-Reimers, E., Quintero-Platt, G., Rodríguez-Gaspar, M., Alemán-Valls, R., Pérez-Hernández, O., Santolaria-Fernández, F. (2015) Liver steatosis in hepatitis C patients. World J Hepatol, 7(10): 1337-46
Goodman, Z., Ishak, K. (1995) Histopathology of Hepatitis C Virus Infection. Seminars in Liver Disease, 15(01): 70-81
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H. (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 61(1): S45-S57
Hwang, S., Lee, S. (2011) Hepatic steatosis and hepatitis C: Still unhappy bedfellows?. Journal of Gastroenterology and Hepatology, 26: 96-101
Irimia, E., Mogoantă, L., Predescu, I.O., Efrem, I.C., Stănescu, C., Streba, L.A., i dr. (2014) Liver steatosis associated with chronic hepatitis C. Rom J Morphol Embryol, 55(2): 351-6
Khan, A.N., Said, K., Ali, K., Gul, R. (2015) Frequency and severity of steatosis in patients with chronic hepatitis-C. J Ayub Med Coll Abbottabad, 27(1): 105-7
Kleiner, D.E., Brunt, E.M., van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., Sanyal, A.J. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41(6): 1313-1321
Lonardo, A. (2014) Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen. World Journal of Gastroenterology, 20(23): 7089
Macaluso, F.S., Maida, M., Minissale, M.G., Li, V.T., Attardo, S., Orlando, E., Petta, S. (2013) Metabolic Factors and Chronic Hepatitis C: A Complex Interplay. BioMed Research International, 2013: 1-12
Mangia, A., Ripoli, M. (2013) Insulin resistance, steatosis and hepatitis C virus. Hepatology International, 7(S2): 782-789
Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., Persico, M. (2015) Non Alcoholic Fatty Liver: Epidemiology and Natural History. Reviews on Recent Clinical Trials, 9(3): 126-133
Matos, C.A., Perez, R.M., Pacheco, M.S., Figueiredo-Mendes, C.G., Lopes-Neto, E., Oliveira, E.B., Lanzoni, V.P., Silva, A.E., Ferraz, M.L. (2006) Steatosis in chronic hepatitis C: Relationship to the virus and host risk factors. Journal of Gastroenterology and Hepatology, 21(8): 1236-1239
Messina, J.P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G.S., Pybus, O.G., Barnes, E. (2014) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology, 61(1): 77-87
Mishra, A., Younossi, Z.M. (2012) Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2(2): 135-144
Modaresi, E.J., Ansari-Gilani, K. (2015) Steatosis and hepatitis C. Gastroenterology Report, 4(1): 24-9
Moroşan, E., Mihailovici, M.S., Giuşcă, S.E., Cojocaru, E., Avădănei, E.R., Căruntu, I.D., i dr. (2014) Hepatic steatosis background in chronic hepatitis B and C - significance of similarities and differences. Rom J Morphol Embryol, 55(3 Supp): 1041-7
Negro, F. (2014) Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology, 61(1): S69-S78
Pais, R., Barritt, A. S., Calmus, Y., Scatton, O., Runge, T., Lebray, P., Poynard, T., Ratziu, V., Conti, F. (2016) NAFLD and liver transplantation: Current burden and expected challenges. Journal of Hepatology, 65(6): 1245-1257
Pais, R., Rusu, E., Zilisteanu, D., Circiumaru, A., Micu, L., Voiculescu, M., Poynard, T., Ratziu, V. (2015) Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. European Journal of Internal Medicine, 26(1): 30-36
Reddy, K.R., Govindarajan, S., Marcellin, P., Bernstein, D., Dienstag, J.L., Bodenheimer, H., i dr. (2008) Hepatic steatosis in chronic hepatitis C: Baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin. J Viral Hepat, 15(2): 129-36
Roingeard, P. (2012) Hepatitis C virus diversity and hepatic steatosis. Journal of Viral Hepatitis, 20(2): 77-84
Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Malé, P., Mentha, G., Spahr, L., Zarski, J., Borisch, B., Hadengue, A., Negro, F. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Journal of Hepatology, 33(1): 106-115
Savvoula, S., Dimitrios, C., George, P., Spilios, M., Christos, T., John, G. (2012) The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C. Gastroenterology Research and Practice, 2012: 1-9
Werling, K., Schaff, Z., Dinya, E., Tulassay, Z. (2010) Effect of Liver Steatosis on Therapeutic Response in Chronic Hepatitis C Virus Genotype 1 Infected Patients in Hungary. Pathology & Oncology Research, 16(2): 149-157
Westbrook, R.H., Dusheiko, G. (2014) Natural history of hepatitis C. Journal of Hepatology, 61(1): S58-S68
Wong, R.J., Gish, R.G. (2016) Metabolic Manifestations and Complications Associated With Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y), 12(5): 293-9
Younossi, Z.M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., Hunt, S. (2015) Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology, 62(6): 1723-1730
Younossi, Z.M., Birerdinc, A., Henry, L. (2016) Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology, 65(1): S109-S119
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/VSP161115031P
objavljen u SCIndeksu: 25.04.2019.
metod recenzije: dvostruko anoniman
Creative Commons License 4.0